Evidence mapPaperPMID 15734832Full record

ReviewDiabetes2005

A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome.

Scott A Summers, Don H Nelson

2 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Diabetes, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 69 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07065383 narecruitingstarted 2025, after this paper: background citation

Intramyocellular Lipid Compartments After Glucagon-like Peptide 1 Receptor Agonist Therapy in Type 2 Diabetes - Rebalancing the Fat Content of the Heart and Muscles

Ran2025Enrolled60Registered outcomes2Posted comparisons0ConditionsDiabetes Mellitus Type 2ArmsSemaglutide administration plus dietary counselling and physical activity encouragement, Semaglutide plus a personalised and supervised program of resistance and endurance training
Open the trial in the graph
NCT03065140 nacompletednot on this mapstarted 2016, after this paper: background citation

Muscle Fat Compartments and Turnover as Determinant of Insulin Sensitivity - the MISTY Study

TypeinterventionalSponsorUniversity of AberdeenRan2016 to 2019Enrolled50ConditionsDiabetesArmsTraining or detraining
3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 1 synthesis or guideline pooled it, 183 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Mechanism of Obesity-Related Lipotoxicity and Clinical Perspective.Advances in experimental medicine and biology · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Scott A SummersDivision of Endocrinology, Metabolism and Diabetes, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132, USA. scott.summers@hsc.utah.edu
Don H Nelson
University of Utah · US

Funding

The role of sphingolipids in insulin signal transductionR01DK058784 · UNIVERSITY OF UTAH · 2001 to 2004
$964k
NIDDK NIH HHS DK-58784
6 · The paper itself

Abstract

Metabolic syndrome X and type 2 diabetes share many metabolic and morphological similarities with Cushing's syndrome, a rare disorder caused by systemic glucocorticoid excess. Pathologies frequently associated with these diseases include insulin resistance, atherosclerosis, susceptibility to infection, poor wound healing, and hypertension. The similarity of the clinical profiles associated with these disorders suggests the influence of a common molecular mechanism for disease onset. Interestingly, numerous studies identify ceramides and other sphingolipids as potential contributors to these sequelae. Herein we review studies demonstrating that aberrant ceramide accumulation contributes to the development of the deleterious clinical manifestations associated with these diseases.

Indexed as

AnimalsCeramidesCushing SyndromeDiabetes Mellitus, Type 2HumansInsulin ResistanceMetabolic SyndromeMolecular StructureCeramides

Identifiers

PMID15734832
OpenAlexW2099744924

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.